Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Stefan Holdenrieder Stories

2013-11-07 08:31:11

Initial study results demonstrate detection rate of 75% for colorectal cancer BALTIMORE, Nov. 7, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces the publication of preliminary data from an ongoing independent trial of one of its NuQ® assays. Priv.-Doz. Dr. Stefan Holdenrieder will present a poster at the eighth CNAPS (Circulating Nucleic Acids in Plasma and Serum)...

2012-07-09 02:24:29

SINGAPORE, July 9, 2012 /PRNewswire/ -- VolitionRX Limited (OTC:VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it has entered into a collaboration agreement with Rheinische Friedrich-Wilhelms-Universitat Bonn ("Bonn University"), Germany. Under the agreement, Priv.-Doz. Dr. Stefan Holdenrieder of the Institute of Clinical Chemistry and Clinical Pharmacology at University Hospital Bonn will undertake multiple independent...